Search - tctmd.com

Displaying 41 - 60 of 76

Sort: Relevancy | Date

Presentation TVT 2022

Case 4: Calcium, Calcium, and More Calcium

Presenter: Joseph Walsh

June 10, 2022

Presentation TVT 2022

JenaValve to treat a degenerative regurgitant aortic valve following previous Ross procedure with no annular calcium.

Presenter: Jubin Joseph

June 09, 2022

Presentation TVT 2022

Forget Sievers, CT Phenotyping and Calcium Reign Supreme in Bicuspid Disease!

Presenter: Hasan Jilaihawi

June 08, 2022

News Daily News

Following Takotsubo, Men Have Worse Outcomes, Are More Likely to Die Than Women

Yael L. Maxwell

June 03, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

L.A. McKeown

May 23, 2022

News Daily News

Coronary Plaque Seen in Half of Asymptomatic Individuals on CTA

Yael L. Maxwell

May 16, 2022

News Daily News

New CAC Risk Tool Helps Contextualize Scores for Younger Adults

Yael L. Maxwell

May 12, 2022

Presentation Fellows 2022

Transfemoral access with IVL

Presenter: Santhosh Mathews

May 06, 2022

Presentation Fellows 2022

Peripheral IVL applications and experience

Presenter: Sahil Parikh

May 06, 2022

Presentation Fellows 2022

Coronary IVL applications and experience

Presenter: Margaret McEntegart

May 06, 2022

Presentation Fellows 2022

IVL…a sound approach

Presenter: Robert Yeh

May 06, 2022

Presentation Fellows 2022

Calcium Treatment Strategies

Presenter: Evan Shlofmitz

May 05, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Presentation ARCH 2022

Introduction to the Calcium Algorithm

Presenter: Jeffrey W. Moses

April 23, 2022

Presentation ARCH 2022

Calcium Management Strategies: From Atherectomy to IVL

Presenter: Anish J. Thomas

April 23, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

Caitlin E. Cox

April 02, 2022

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

News Conference News ACC 2022

Can a Smartphone App Use Voice Patterns to Predict CAD Events?

Caitlin E. Cox

March 24, 2022

Advertisement

Case 4: Calcium, Calcium, and More Calcium

JenaValve to treat a degenerative regurgitant aortic valve following previous Ross procedure with no annular calcium.

Forget Sievers, CT Phenotyping and Calcium Reign Supreme in Bicuspid Disease!

Following Takotsubo, Men Have Worse Outcomes, Are More Likely to Die Than Women

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

Coronary Plaque Seen in Half of Asymptomatic Individuals on CTA

New CAC Risk Tool Helps Contextualize Scores for Younger Adults

Transfemoral access with IVL

Peripheral IVL applications and experience

Coronary IVL applications and experience

IVL…a sound approach

Calcium Treatment Strategies

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Introduction to the Calcium Algorithm

Calcium Management Strategies: From Atherectomy to IVL

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

In ANOCA, Diltiazem Fails to Improve Vasomotor Function: EDIT-CMD

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Can a Smartphone App Use Voice Patterns to Predict CAD Events?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content